PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项多机构、I期、递增研究，旨在评价芬维A胺IV给药（每3周一次，持续5天）治疗恶性实体瘤的安全性和耐受性。将确定MTD，并将沿着单核细胞试验评估药代动力学。将尽可能评估肿瘤缓解。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-institutional, phase I,escalating study of safety and tolerability of IV fenretinide given over 5 days every 3 weeks in solid tumor malignanies. MTD will be determined and pharmacokinetics will be assessed along with mononuclear cell assays. Tumor response will be assessed whever possible.